Table 2.
Comparison of pre- and postintervention kidney function and contrast-induced acute renal injury between those who received evolocumab and controls.
| Control group (n = 160) | Evolocumab group (n = 149) | χ 2/t/Z | p value | |
|---|---|---|---|---|
| Pre-PCI Cr (μmol/L), median (IQR) | 78.00 (67.00–89.00) | 78.00 (65.00–87.5) | −0.96 | 0.34 |
| Post-PCI Cr (μmol/L), median (IQR) | 86.00 (73.00–99.00) | 80.00 (69.00–90.00) | −3.69 | <0.01 |
| Cr change pre- to post-PCI (%), median (IQR) | 7.14 (1.12–20.26) | 3.45 (−1.18–12.79) | −3.28 | <0.01 |
| CI-AKI, n (%) | 32 (20.00) | 10 (6.70) | 11.60 | <0.01 |
χ 2/t/Z, a test used to compare parameters. IQR, interquartile range; PCI, percutaneous coronary intervention; Cr, creatinine; CI-AKI, contrast-induced acute renal injury.